PERSANTINE SOLUTION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

DIPYRIDAMOLE

Pieejams no:

GLENWOOD GMBH PHARMAZEUTISCHE ERZEUGNISSE

ATĶ kods:

B01AC07

SNN (starptautisko nepatentēto nosaukumu):

DIPYRIDAMOLE

Deva:

5MG

Zāļu forma:

SOLUTION

Kompozīcija:

DIPYRIDAMOLE 5MG

Ievadīšanas:

INTRAVENOUS

Vienības iepakojumā:

15G/50G

Receptes veids:

Prescription

Ārstniecības joma:

MISCELLANEOUS VASODILATATING AGENTS

Produktu pārskats:

Active ingredient group (AIG) number: 0106621005; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2020-11-30

Produkta apraksts

_ _
_PERSANTINE Dipyridamole_
_ _
_Product Monograph_
_ _
_Page 1 of 27 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
PERSANTINE
®
Dipyridamole for Injection
Solution, 5 mg/mL, intravenous
Coronary Vasodilator
Inhibitor of Platelet Adhesion and Aggregation
Manufactured by:
Glenwood GmbH Pharmazeutische Erzeugnisse
Arabellastr. 17
81925 Munich
Germany
Date of Initial Authorization:
Aug 30, 1960
Date of Revision:
October 31, 2023
Imported by:
McKesson Specialized Distribution Inc.
8449 Lawson Rd, Unit 102
Milton, Ontario L9T 9L1
Submission Control Number: 276658
_ _
_PERSANTINE Dipyridamole Product Monograph _
_Page 2 of 27 _
RECENT MAJOR LABEL CHANGES
Not applicable.
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.............................................................................................
2
TABLE OF CONTENTS
...............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1
INDICATIONS
................................................................................................................
4
1.1 PEDIATRICS
....................................................................................................................
4
2
CONTRAINDICATIONS
..................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................. 4
4
DOSAGE AND ADMINISTRATION
..................................................................................
4
4.1 DOSING CONSIDERATIONS
................................................................................................
4
4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT
........................................................... 4
4.3 RECONSTITUTION
.........................